SCHEMBL1470951

SCHEMBL1470951

CC(C)(C)OC(=O)N(CCNc1ccccc1NC(=O)NCc1ccccc1)Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 2/20 0.46
HDAC3 O15379 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
NCOR2 Q9Y618 2/20 0.46
POLB P06746 2/20 0.46
CFD P00746 1/20 0.44
GSK3B P49841 1/20 0.44
BACE1 P56817 3/20 0.40
SNCA P37840 1/20 0.40
NAMPT P43490 1/20 0.39
LMNA P02545 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
TRPV1 Q8NER1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471034 0.88 HDAC3 (0.47) KDM4EALDH1A1HDAC3HDAC1HDAC2
SCHEMBL1471319 0.81 HDAC1 (0.50) KDM4EHDAC3HDAC1HDAC2NCOR2
SCHEMBL7206187 0.80 HDAC3 (0.55) KDM4EGAAHDAC3HDAC1HDAC2
SCHEMBL1470808 0.78 HDAC3 (0.47) ALDH1A1GAAHDAC3HDAC1HDAC2
SCHEMBL7202865 0.75 CCR6 (0.58) KDM4EGAAHDAC3HDAC1HDAC2
SCHEMBL31248371 0.75 HDAC1 (0.52) ALDH1A1GAAHDAC3HDAC1HDAC2
SCHEMBL7205254 0.74 CCR6 (0.57) KDM4EGAAHDAC3HDAC1HDAC2
SCHEMBL4147838 0.74 HDAC1 (0.56) ALDH1A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL8619045 0.74 HDAC1 (0.54) HDAC3HDAC1HDAC2NCOR2BACE1
SCHEMBL7207519 0.73 CCR6 (0.56) KDM4EGAAHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20080009521-A1 Aryl Piperidine Amides HUANG CHARLES Q 2008-01-10 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
EP-1660472-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
WO-2005021525-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-10 WO disclosed
US-20050049239-A1 Aryl piperidine amides JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009521-A1 Aryl Piperidine Amides BDNF, NTRK2, OPRL1 KDM4E 2106/4885ALDH1A1 952/4885GAA 1523/4885
US-20050049239-A1 Aryl piperidine amides BDNF, NTRK2, OPRL1 KDM4E 2106/4885ALDH1A1 952/4885GAA 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.